Skip to content
    RVMD
    Earnings call· Jun 2025(Q2 FY25)

    Revolution Medicines Q2 FY25 earnings call RVMD

    Aug 6, 2025 Source

    Executive summary

    Revolution Medicines Q2 FY25 — Pipeline Progress and Bolstered Financial Position

    Revolution Medicines is advancing its pipeline of RAS(ON) inhibitors, with Daraxonrasib and Elironrasib receiving Breakthrough Therapy designations, underscoring their potential in RAS-addicted cancers. The company significantly bolstered its financial position with a $2 billion Royalty Pharma partnership, enabling independent global development and commercialization. While operating expenses and net loss increased due to expanded clinical and commercial efforts, the company remains focused on becoming a fully integrated oncology leader.

    Highlights

    5

    • Daraxonrasib received Breakthrough Therapy designation from the FDA for previously treated metastatic pancreatic cancer with KRAS G12 mutations.

    • Elironrasib received Breakthrough Therapy designation from the FDA for locally advanced or metastatic KRAS G12C non-small cell lung cancer.

    • Secured $2 billion in committed capital through a flexible synthetic royalty and debt arrangement with Royalty Pharma, bolstering financial strength.

    • RESOLUTE 302 (Daraxonrasib Phase III in 2L PDAC) enrollment is progressing well and expected to complete this year for a 2026 data readout.

    • Advanced multiple clinical programs, including Daraxonrasib, Elironrasib, and Zoldonrasib, with promising data and ongoing registrational trial planning.

    Concerns

    4

    • GAAP net loss for Q2 FY25 increased to $247.8 million compared to $133.2 million in Q2 FY24, primarily due to higher operating expenses.

    • Full-year 2025 GAAP net loss guidance updated to between $1.03 billion and $1.09 billion, an increase driven by independent global development and commercialization plans.

    • R&D expenses for Q2 FY25 increased to $224.1 million compared to $134.9 million in Q2 FY24, mainly due to clinical trial and manufacturing costs for three clinical-stage programs.

    • G&A expenses for Q2 FY25 increased to $40.6 million compared to $21.7 million in Q2 FY24, due to increased headcount and commercial preparation activities.

    Guidance & targets

    9
    CategoryTargetConfidence
    Full-year 2025 GAAP Net Loss
    $1.03 billion and $1.09 billion
    high materiality
    High
    Estimated Noncash Stock-Based Compensation Expense
    $115 million and $130 million
    medium materiality
    High
    RESOLUTE 302 (2L PDAC Phase III) Enrollment Completion
    this year
    high materiality
    High
    RESOLUTE 302 (2L PDAC Phase III) Data Readout
    2026
    high materiality
    High
    First-line Metastatic PDAC Registrational Trial Initiation
    Later this year
    high materiality
    High
    Adjuvant PDAC Registrational Trial Initiation
    Later this year
    high materiality
    High
    First-line NSCLC Registrational Trial Initiation
    2026
    high materiality
    High
    RMC5127 (RAS(ON) G12D selective inhibitor) Clinic Readiness
    later this year
    medium materiality
    High
    RMC5127 Phase I Trial Initiation
    2026
    medium materiality
    High

    Operational metrics

    5
    Cash and Investments Balance
    $2.1 billion
    Q2 FY25

    Includes the receipt of the first royalty monetization tranche of $250 million from the partnership with Royalty Pharma.

    R&D Expenses
    $224.1 millionvs $134.9 million in Q2 FY24
    Q2 FY25

    Primarily due to increases in clinical trial-related expenses and manufacturing expenses for three clinical stage programs, with Daraxonrasib being the largest driver, and increased personnel-related expenses and stock-based compensation.

    G&A Expenses
    $40.6 millionvs $21.7 million in Q2 FY24
    Q2 FY25

    Primarily due to increases in personnel-related expenses and stock-based compensation associated with additional headcount and commercial preparation activities.

    Net Loss
    $247.8 millionvs $133.2 million in Q2 FY24
    Q2 FY25

    The increase was primarily driven by higher operating expenses.

    Noncash Interest Expense
    $900,000
    Q2 FY25

    Related to the $250 million royalty monetization tranche received in June, accounted for as a liability on the balance sheet. Expected to grow for the remainder of the year.

    Industry KPIs

    1
    MetricValueDetails
    Clinical trial efficacy safety dataHighly competitive profile including differentiated safety and tolerability along with a compelling objective response rate and progression-free survival

    Deals & partnerships

    5
    Royalty PharmaFunding arrangement providing $2 billion in committed capital, comprised of up to $1.25 billion in synthetic royalty on future sales of Daraxonrasib and up to $750 million in corporate debt.$2 billion

    Bolsters financial strength for independent global development and commercialization strategy. Accounting for the first tranche as a liability, with noncash interest expense recognized.

    Tango TherapeuticsClinical collaboration to evaluate their PRMT5 inhibitor TNG 462 with either Daraxonrasib or Zoldonrasib.

    Focus on patients with pancreatic cancer carrying both a RAS mutation and deletion of MTAP. Aims to provide differentiated options for specific cancer genotypes.

    Summit TherapeuticsNew clinical collaboration to evaluate combinations of Ivonetumab (PD-1 VEGF bispecific antibody) with Daraxonrasib, Elironrasib, and Zoldonrasib.

    Builds on promising initial clinical evidence of additive antitumor activity with PD-1 antibodies. Aims to unlock further therapeutic impact with a next-generation bispecific inhibitor.

    AthonCollaboration to discover novel bispecific antibodies that can complement RAS(ON) inhibitors.

    Enhances discovery efforts.

    IambicSignificant drug discovery collaboration to use their cutting-edge AI capabilities and generate customized models through training with Revolution Medicines' proprietary data.

    Aims to enhance lead discovery and optimization processes directed against current and new drug targets, leveraging AI to process massive proprietary data sets more efficiently.

    Risks & headwinds

    2
    RAS amplification (of the mutant allele) as a mechanism of escape from RAS inhibitors.

    Major force of escape

    Mitigation: Can be overcome by therapeutic ways, such as RAS(ON) inhibitor doublets, which are clinically testing. Mutant RAS amplification is unfavorable for the tumor and takes time to become apparent.

    Chemotherapy toxicities causing dose interruptions and potentially reducing the dose intensity of the RAS inhibitor in combination regimens.Ongoing in combination studies

    Discussed qualitatively

    Mitigation: Primary consideration in designing combination regimens is minimizing dose interruptions and maximizing RAS inhibitor dose intensity, using standard practice chemotherapy doses and schedules.

    What to watch in Q3 FY25

    5

    RESOLUTE 302 Enrollment Completion

    This year (CY25)
    CurrentEnrollment winding down in U.S., continuing ex-U.S.
    TargetEnrollment completed

    Why it matters

    Completion of enrollment is a key milestone for the Phase III trial, enabling the expected data readout in 2026 and advancing Daraxonrasib towards potential approval.

    RESOLUTE 302, our ongoing global Phase III trial in patients with second-line metastatic pancreatic ductal adenocarcinoma or PDAC, has been enrolling well, and we expect to complete enrollment this year to enable an expected data readout in 2026.

    Q&A highlights

    8

    Inquired about progress on ex-U.S. enrollment for RESOLUTE 302 and geographic distribution, and the role of efficacy assessment for chemotherapy combinations in the planned 3-arm first-line PDAC trial.

    RESOLUTE 302 enrollment is progressing well, with U.S. winding down and ex-U.S. continuing, but specific geographic breakdown cannot be shared. For the first-line PDAC trial, chemo combinations are still being studied, and efficacy data will inform the trial design, though safety and tolerability are primary considerations for dose intensity.

    “We are still studying the chemo combinations, but we're very -- we did promise that we would share the study design and the rationale behind that study design in 2025. We're getting closer to the end of 2025. So -- so you can infer that we're pretty close to the end of the assessments that we need in order to inform the study design specifically with regards to the efficacy assessments explicitly.”

    asked by Michael Schmidt · answered by Stephen Kelsey

    2 min read6 chapters

    Detailed Narrative

    01

    RAS(ON) Inhibitor Pipeline Overview

    Revolution Medicines is focused on developing RAS(ON) inhibitors for RAS-addicted cancers, with a pipeline including Daraxonrasib (multi-selective), Elironrasib (G12C selective), and Zoldonrasib (G12D selective). Zoldonrasib's innovative chemistry and biological impact in preclinical models were recently published in Science. The company aims to transform treatment for patients with RAS-driven cancers.

    02

    Daraxonrasib in Pancreatic Cancer

    Daraxonrasib received Breakthrough Therapy designation for previously treated metastatic pancreatic cancer with KRAS G12 mutations. The global Phase III RESOLUTE 302 trial in second-line PDAC is enrolling well, with U.S. enrollment winding down and data expected in 2026. Plans are progressing for a first-line metastatic PDAC registrational trial (3-arm, Daraxonrasib +/- chemotherapy vs. chemotherapy) and an adjuvant PDAC registrational trial, both expected to initiate later this year.

    03

    Daraxonrasib in Non-Small Cell Lung Cancer (NSCLC)

    The RESOLUTE 301 Phase III trial for Daraxonrasib in previously treated RAS-mutant NSCLC continues enrollment in the U.S., with sites activating in Europe and Japan. Clinical evidence supports combining Daraxonrasib with pembrolizumab (with or without platinum-doublet chemotherapy), informing plans for a first-line NSCLC registrational trial in 2026.

    04

    Elironrasib and Zoldonrasib Progress

    Elironrasib, a G12C selective inhibitor, received Breakthrough Therapy designation for locally advanced or metastatic KRAS G12C NSCLC. Updated monotherapy data showed a competitive profile with differentiated safety/tolerability and compelling ORR/PFS. Elironrasib also demonstrated significant antitumor activity in combination with Daraxonrasib in G12C OFF inhibitor-progressed NSCLC and colorectal cancer patients, and productively combined with pembrolizumab in first-line NSCLC. Zoldonrasib, a G12D selective inhibitor, showed promising data in previously treated RAS G12D NSCLC, with an expansion cohort ongoing and combination settings being explored.

    05

    Next-Generation Pipeline and AI Collaboration

    RMC5127, a RAS(ON) G12D selective inhibitor, is expected to be clinic-ready later this year, with Phase I initiation planned for 2026. The company is investing in next-generation assets and collaborations, including with Athon for novel bispecific antibodies and Iambic for AI-driven drug discovery. The Iambic collaboration leverages AI to enhance lead discovery and optimization by training customized models with Revolution Medicines' proprietary data.

    06

    Financial Strength and Commercialization Strategy

    A $2 billion partnership with Royalty Pharma, comprising synthetic royalty and corporate debt, significantly bolsters financial strength and provides flexible capital access without equity dilution. This funding supports the company's independent global development and commercialization strategy, aiming to establish Revolution Medicines as a fully integrated global oncology company. Pre-commercial activities are underway, focusing on market shaping, KOL engagement, and building U.S. field teams.

    AI-generated summary of the company’s earnings call. Not investment advice.